Drugs / BIC/FTC/TAF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05606055 | Dec 2020 → Feb 2021 | HIV infectious disease | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIC/FTC/TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05606055 ↗ |
| Known as | Bictegravir/emtricitabina/tenofovir alafenamida fumarato | “BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato” NCT05606055 ↗ |
| Route | Oral | “orally, once a day” NCT05606055 ↗ |